LATTICE-BASED PUBLIC KEY CRYPTOSYSTEM AND ELECTRONIC DEVICE INCLUDED IN THE SAME

    公开(公告)号:US20250015992A1

    公开(公告)日:2025-01-09

    申请号:US18516691

    申请日:2023-11-21

    Inventor: Kyung Ah SHIM

    Abstract: Embodiments of the present disclosure may include a key generation device of a lattice-based public key cryptosystem. In some embodiments, the key generation device may include a communication unit, a storage unit, and a processor that may be configured to control the key generation device to perform operations. In some embodiments, the operations may include generating a public key by using a public key polynomial, where the public key polynomial may belong to a first polynomial ring. In some embodiments, the operations may additionally include generating a secret key that may correspond to the public key. In some embodiments, the secret key may be generated by using a secret key polynomial that may belong to a second polynomial ring. In some embodiments, the operations may additionally include storing the public key and the secret key.

    Structural and functional characteristics of yeast-derived polysaccharide inducing Treg cell

    公开(公告)号:US12161662B2

    公开(公告)日:2024-12-10

    申请号:US17285253

    申请日:2019-07-29

    Abstract: The present invention relates to a yeast-derived polysaccharide inducing Treg cells and a use thereof and, more particularly, to a polysaccharide comprising mannan and β-glucan, an composition for immunomodulation comprising the polysaccharide as an active ingredient, a pharmaceutical composition or food comprising the polysaccharide as an active ingredient for prevention or treatment of immune disease or inflammatory disease, a method for preparation of regulatory T cells by using the polysaccharide, a cell therapeutic agent comprising the regulatory T cells prepared by the preparation method as an active ingredient, and a treatment method using same. Even at a low dose, the novel polysaccharide according to the present invention allows the production of tolerogenic antigen presenting cells through the β-glucan and mannan structure retained therein, whereby the novel polysaccharide can induce the differentiation or production of antigen-specific regulatory T cells (Treg cells) to modulate the target immune system with low adverse effects. Therefore, MGCP and the Treg cells induced by the polysaccharide are effective for preventing or treating immune disease or inflammatory disease.

Patent Agency Ranking